Protocol Ledger

NCT07804186 · Phase III · RECRUITING

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

Interventional Phase III clinical trial protocol NCT07804186 sponsored by IDEAYA Biosciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-01 Enrollment: 450 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07804186
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)450 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07804186
Protocol FieldVerified Registry Value
NCT IdentifierNCT07804186
Consolidated Lead SponsorIDEAYA Biosciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment450 participants (ESTIMATED)
Registered Start Date2026-09-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI